肺がんリキッドバイオプシーの世界市場レポート2025年

肺がんリキッドバイオプシーの市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16.8％で20億8,000万米ドルに成長します。予測期間の成長は、肺がん罹患率の上昇、非侵襲的診断法に対する需要の増加、個別化医療の採用拡大、がん早期発見に対する意識の高まり、がんに罹患しやすい老年人口の増加などに起因しています。この期間に予想される主な動向には、循環腫瘍DNA（ctDNA）分析技術の進歩、エクソソームベースのリキッドバイオプシー技術の進歩、循環腫瘍細胞を分離するためのマイクロ流体工学の革新、バイオマーカー解釈のためのAIと機械学習の統合、マルチプレックスバイオマーカー分析を可能にする技術的ブレークスルーなどがあります。

肺がんの罹患率の上昇は、今後数年間の肺がんリキッドバイオプシー市場の成長を促進すると予想されます。肺がんは、肺における異常細胞の制御不能な増殖によって特徴づけられる病態であり、一般に喫煙や環境曝露と関連しています。患者数の増加は主に、異常な細胞増殖を開始させる発がん物質に肺をさらすタバコの継続的な使用に起因しています。肺がんのリキッドバイオプシーは、シンプルな血液サンプルを通じてがんに関連する遺伝子変異や腫瘍DNAを検出することを可能にし、早期診断、個別化治療の選択、疾患の進行や治療効果の継続的なモニタリングを容易にします。例えば、2023年、米国がん協会は、2022年1月1日現在、米国では65万4,620人が肺がんの既往歴があり、その多くが転移性疾患を抱えて生活していると報告しました。これらの患者の約80％は65歳以上であり、55％は過去5年以内に診断されており、生存率の低さを反映しています。その結果、肺がん罹患率の増加が肺がんリキッドバイオプシー市場の拡大に大きく寄与しています。

肺がんリキッドバイオプシー市場の主要企業は、早期発見、診断精度の向上、腫瘍の進行や治療反応の非侵襲的なリアルタイムモニタリングの提供を目的として、血液ベースの肺がんスクリーニング検査の市場開拓などの技術進歩を優先しています。このような血液ベースのスクリーニング検査は、血流中のバイオマーカーを分析して肺がんを早期発見するもので、従来の方法よりも侵襲性の低い代替手段を提供します。例えば、米国を拠点とするバイオテクノロジー企業DELFI Diagnostics Inc.は2023年10月、肺がんの早期発見を目的とした血液ベースのリキッドバイオプシー検査であるFirstLook Lungを発表しました。この検査はフラグメントミクスを利用し、高い感度と99.8％の陰性的中率で早期肺がんを同定します。この検査は、早期発見率を向上させ、検診への参加を促進し、最も恩恵を受ける可能性の高い人々への画像診断リソースの優先順位付けを支援することを目的として、リスクのある人々にとって利用しやすく便利な初期スクリーニング・ツールとして機能するように設計されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の肺がんリキッドバイオプシー：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の肺がんリキッドバイオプシー市場：成長率分析
• 世界の肺がんリキッドバイオプシー市場の実績：規模と成長, 2019-2024
• 世界の肺がんリキッドバイオプシー市場の予測：規模と成長, 2024-2029, 2034F
• 世界の肺がんリキッドバイオプシー：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の肺がんリキッドバイオプシー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機器
• 消耗品キットおよび試薬
• ソフトウェアとサービス
• 世界の肺がんリキッドバイオプシー市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マルチ遺伝子並列解析（NGS）
• 単一遺伝子解析（PCRマイクロアレイ）
• 世界の肺がんリキッドバイオプシー市場バイオマーカー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遊離デオキシリボ核酸
• 循環腫瘍デオキシリボ核酸
• 細胞外小胞
• 循環腫瘍細胞
• その他のバイオマーカー
• 世界の肺がんリキッドバイオプシー市場臨床応用による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 治療法の選択
• 治療モニタリング
• 早期がん検診
• 再発モニタリング
• その他の用途
• 世界の肺がんリキッドバイオプシー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断および画像診断センター
• 病院
• 学術研究センター
• その他のエンドユーザー
• 世界の肺がんリキッドバイオプシー市場、楽器の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PCR機器
• マイクロアレイ機器
• 次世代シーケンシング（NGS）機器
• 世界の肺がんリキッドバイオプシー市場消耗品キットおよび試薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サンプル採取キット
• 増幅試薬
• シーケンシング試薬
• 世界の肺がんリキッドバイオプシー市場ソフトウェアとサービスのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• データ分析ソフトウェア
• クラウドベースのサービス
• バイオインフォマティクスツール

第7章 地域別・国別分析

• 世界の肺がんリキッドバイオプシー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の肺がんリキッドバイオプシー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 肺がんリキッドバイオプシー市場：競合情勢
• 肺がんリキッドバイオプシー市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Illumina Inc.
• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Exact Sciences Corp
• Natera Inc.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• Guardant Health Inc.
• MDxHealth SA
• Exosome Diagnostics Inc.
• Menarini Silicon Biosystems S.p.A.
• Inivata Ltd
• Lucence Diagnostics Pte Ltd
• LungLife AI Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 肺がんリキッドバイオプシー市場2029：新たな機会を提供する国
• 肺がんリキッドバイオプシー市場2029：新たな機会を提供するセグメント
• 肺がんリキッドバイオプシー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Lung cancer liquid biopsy is a non-invasive method that examines blood or other bodily fluids to identify tumor-derived genetic material or cells. This technique supports early detection, genetic profiling, and monitoring of lung cancer by capturing cancer-specific biomarkers, providing an alternative to traditional surgical tissue biopsies.

Lung cancer liquid biopsy products include instruments, consumables kits and reagents, and software and services. Instruments refer to the hardware and analytical tools used to process and evaluate liquid biopsy samples. The technology applied includes multi-gene parallel analysis methods such as next-generation sequencing (NGS) and single-gene techniques like PCR and microarrays. Biomarkers analyzed include cell-free DNA, circulating tumor DNA, extracellular vesicles, circulating tumor cells, and other related indicators. These biomarkers are utilized for various purposes, including therapy selection, treatment monitoring, early cancer detection, recurrence surveillance, and other clinical applications. End-users include diagnostic and imaging centers, hospitals, academic and research institutions, and other relevant facilities.

The lung cancer liquid biopsy market research report is one of a series of new reports from The Business Research Company that provides lung cancer liquid biopsy market statistics, including the lung cancer liquid biopsy industry's global market size, regional shares, competitors with the lung cancer liquid biopsy market share, detailed lung cancer liquid biopsy market segments, market trends and opportunities, and any further data you may need to thrive in the lung cancer liquid biopsy market. This lung cancer liquid biopsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer liquid biopsy market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.12 billion in 2025 at a compound annual growth rate (CAGR) of 17.0%. Growth during the historic period can be attributed to the increasing prevalence of smoking- and pollution-related lung disorders, expanded use of liquid biopsy for treatment monitoring, growing investment in oncology research and development, rising demand for rapid and cost-effective diagnostic solutions, and an increasing number of clinical trials.

The lung cancer liquid biopsy market size is expected to see rapid growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. Growth in the forecast period can be attributed to the rising incidence of lung cancer, increasing demand for non-invasive diagnostic methods, growing adoption of personalized medicine, heightened awareness of early cancer detection, and a rising geriatric population more vulnerable to cancer. Key trends expected during this period include advancements in circulating tumor DNA (ctDNA) analysis technologies, progress in exosome-based liquid biopsy techniques, innovations in microfluidics for isolating circulating tumor cells, the integration of AI and machine learning for biomarker interpretation, and technological breakthroughs enabling multiplex biomarker analysis.

The rising incidence of lung cancer is expected to drive the growth of the lung cancer liquid biopsy market in the coming years. Lung cancer is a condition marked by the uncontrolled proliferation of abnormal cells in the lungs, commonly linked to smoking and environmental exposures. The increasing number of cases is primarily attributed to continued tobacco use, which exposes the lungs to carcinogens that initiate abnormal cell growth. Liquid biopsy for lung cancer enables the detection of cancer-related genetic mutations and tumor DNA through a simple blood sample, facilitating early diagnosis, personalized treatment selection, and ongoing monitoring of disease progression or therapeutic response. For example, in 2023, the American Cancer Society reported that as of January 1, 2022, 654,620 individuals in the U.S. had a history of lung cancer, with many living with metastatic disease. Approximately 80% of these patients were aged 65 or older, and 55% had been diagnosed within the past five years, reflecting low survival rates. Consequently, the growing incidence of lung cancer is significantly contributing to the expansion of the lung cancer liquid biopsy market.

Major companies in the lung cancer liquid biopsy market are prioritizing technological advancements, such as the development of blood-based lung cancer screening tests, to improve early detection, enhance diagnostic accuracy, and provide non-invasive, real-time monitoring of tumor progression and treatment response. These blood-based screening tests analyze biomarkers in the bloodstream to detect lung cancer at an early stage, offering a less invasive alternative to traditional methods. For example, in October 2023, DELFI Diagnostics Inc., a U.S.-based biotechnology company, introduced FirstLook Lung-a blood-based liquid biopsy test aimed at early lung cancer detection. This test utilizes fragmentomics to identify early-stage lung cancer with high sensitivity and a 99.8% negative predictive value. It is designed to serve as an accessible and convenient initial screening tool for individuals at risk, with the goal of improving early detection rates, boosting screening participation, and helping prioritize imaging resources for those most likely to benefit.

In February 2024, Veracyte Inc., a U.S.-based molecular diagnostics company, acquired C2i Genomics Inc. for an undisclosed amount. Through this acquisition, Veracyte seeks to strengthen its cancer diagnostics portfolio by incorporating advanced whole-genome minimal residual disease (MRD) liquid biopsy technology to improve detection and monitoring across various cancer types. C2i Genomics Inc. is a U.S.-based company specializing in cancer detection and monitoring, including liquid biopsy tests for lung cancer.

Major players in the lung cancer liquid biopsy market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Biocept Inc., Agilent Technologies Inc., Eurofins Scientific, Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corp, Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., MDxHealth SA, Exosome Diagnostics Inc., Menarini Silicon Biosystems S.p.A., Inivata Ltd, Lucence Diagnostics Pte Ltd, LungLife AI Inc., Biodesix Inc., Oncocyte Corporation.

North America was the largest region in the lung cancer liquid biopsy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer liquid biopsy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lung cancer liquid biopsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lung cancer liquid biopsy market consists of revenues earned by entities by providing services such as mutation detection and genomic profiling, treatment monitoring, and early diagnosis and screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The lung cancer liquid biopsy market also includes sales of NGS-based assays, CTC detection devices and others. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lung Cancer Liquid Biopsy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lung cancer liquid biopsy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lung cancer liquid biopsy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lung cancer liquid biopsy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Instruments; Sconsumables Kits And Reagents; Software And Services
• 2) By Technology: Multi Gene-Parallel Analysis (Ngs); Single Gene Analysis (Pcr Microarrays)
• 3) By Biomarker: Cell-Free Deoxyribonucleic Acid; Circulating Tumor Deoxyribonucleic Acid; Extracellular Vesicles; Circulating Tumor Cells; Other Biomarkers
• 4) By Clinical Application: Therapy Selection; Treatment Monitoring; Early Cancer Screening; Recurrence Monitoring; Other Applications
• 5) By End User: Diagnostics And Imaging Centres; Hospitals; Academics And Research Centres; Other End Users
• Subsegments:
• 1) By Instruments: Pcr Instruments; Microarray Instruments; Next-Generation Sequencing (Ngs) Instruments
• 2) By Consumables Kits And Reagents: Sample Collection Kits; Amplification Reagents; Sequencing Reagents
• 3) By Software And Services: Data Analysis Software; Cloud-Based Services; Bioinformatics Tools
• Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Biocept Inc.; Agilent Technologies Inc.; Eurofins Scientific
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Lung Cancer Liquid Biopsy Market Characteristics

3. Lung Cancer Liquid Biopsy Market Trends And Strategies

4. Lung Cancer Liquid Biopsy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lung Cancer Liquid Biopsy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Lung Cancer Liquid Biopsy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Lung Cancer Liquid Biopsy Market Growth Rate Analysis
• 5.4. Global Lung Cancer Liquid Biopsy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Lung Cancer Liquid Biopsy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Lung Cancer Liquid Biopsy Total Addressable Market (TAM)

6. Lung Cancer Liquid Biopsy Market Segmentation

• 6.1. Global Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Instruments
• Sconsumables Kits And Reagents
• Software And Services
• 6.2. Global Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multi Gene-Parallel Analysis (Ngs)
• Single Gene Analysis (Pcr Microarrays)
• 6.3. Global Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cell-Free Deoxyribonucleic Acid
• Circulating Tumor Deoxyribonucleic Acid
• Extracellular Vesicles
• Circulating Tumor Cells
• Other Biomarkers
• 6.4. Global Lung Cancer Liquid Biopsy Market, Segmentation By Clinical Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Other Applications
• 6.5. Global Lung Cancer Liquid Biopsy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnostics And Imaging Centres
• Hospitals
• Academics And Research Centres
• Other End Users
• 6.6. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pcr Instruments
• Microarray Instruments
• Next-Generation Sequencing (Ngs) Instruments
• 6.7. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Consumables Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sample Collection Kits
• Amplification Reagents
• Sequencing Reagents
• 6.8. Global Lung Cancer Liquid Biopsy Market, Sub-Segmentation Of Software And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Data Analysis Software
• Cloud-Based Services
• Bioinformatics Tools

7. Lung Cancer Liquid Biopsy Market Regional And Country Analysis

• 7.1. Global Lung Cancer Liquid Biopsy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Lung Cancer Liquid Biopsy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Lung Cancer Liquid Biopsy Market

• 8.1. Asia-Pacific Lung Cancer Liquid Biopsy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Lung Cancer Liquid Biopsy Market

• 9.1. China Lung Cancer Liquid Biopsy Market Overview
• 9.2. China Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Lung Cancer Liquid Biopsy Market

• 10.1. India Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Lung Cancer Liquid Biopsy Market

• 11.1. Japan Lung Cancer Liquid Biopsy Market Overview
• 11.2. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Lung Cancer Liquid Biopsy Market

• 12.1. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Lung Cancer Liquid Biopsy Market

• 13.1. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Lung Cancer Liquid Biopsy Market

• 14.1. South Korea Lung Cancer Liquid Biopsy Market Overview
• 14.2. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Lung Cancer Liquid Biopsy Market

• 15.1. Western Europe Lung Cancer Liquid Biopsy Market Overview
• 15.2. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Lung Cancer Liquid Biopsy Market

• 16.1. UK Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Lung Cancer Liquid Biopsy Market

• 17.1. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Lung Cancer Liquid Biopsy Market

• 18.1. France Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Lung Cancer Liquid Biopsy Market

• 19.1. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Lung Cancer Liquid Biopsy Market

• 20.1. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lung Cancer Liquid Biopsy Market

• 21.1. Eastern Europe Lung Cancer Liquid Biopsy Market Overview
• 21.2. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Lung Cancer Liquid Biopsy Market

• 22.1. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Lung Cancer Liquid Biopsy Market

• 23.1. North America Lung Cancer Liquid Biopsy Market Overview
• 23.2. North America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Lung Cancer Liquid Biopsy Market

• 24.1. USA Lung Cancer Liquid Biopsy Market Overview
• 24.2. USA Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Lung Cancer Liquid Biopsy Market

• 25.1. Canada Lung Cancer Liquid Biopsy Market Overview
• 25.2. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Lung Cancer Liquid Biopsy Market

• 26.1. South America Lung Cancer Liquid Biopsy Market Overview
• 26.2. South America Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Lung Cancer Liquid Biopsy Market

• 27.1. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Lung Cancer Liquid Biopsy Market

• 28.1. Middle East Lung Cancer Liquid Biopsy Market Overview
• 28.2. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Lung Cancer Liquid Biopsy Market

• 29.1. Africa Lung Cancer Liquid Biopsy Market Overview
• 29.2. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Lung Cancer Liquid Biopsy Market, Segmentation By Biomarker, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Lung Cancer Liquid Biopsy Market Competitive Landscape And Company Profiles

• 30.1. Lung Cancer Liquid Biopsy Market Competitive Landscape
• 30.2. Lung Cancer Liquid Biopsy Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Biocept Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eurofins Scientific Overview, Products and Services, Strategy and Financial Analysis

31. Lung Cancer Liquid Biopsy Market Other Major And Innovative Companies

• 31.1. Illumina Inc.
• 31.2. Sysmex Corporation
• 31.3. Bio-Rad Laboratories Inc.
• 31.4. QIAGEN N.V.
• 31.5. Exact Sciences Corp
• 31.6. Natera Inc.
• 31.7. Myriad Genetics Inc.
• 31.8. NeoGenomics Laboratories Inc.
• 31.9. Guardant Health Inc.
• 31.10. MDxHealth SA
• 31.11. Exosome Diagnostics Inc.
• 31.12. Menarini Silicon Biosystems S.p.A.
• 31.13. Inivata Ltd
• 31.14. Lucence Diagnostics Pte Ltd
• 31.15. LungLife AI Inc.

32. Global Lung Cancer Liquid Biopsy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lung Cancer Liquid Biopsy Market

34. Recent Developments In The Lung Cancer Liquid Biopsy Market

35. Lung Cancer Liquid Biopsy Market High Potential Countries, Segments and Strategies

• 35.1 Lung Cancer Liquid Biopsy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Lung Cancer Liquid Biopsy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Lung Cancer Liquid Biopsy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer